ORIGINAL ARTICLES |
|
|
|
|
|
Genotoxicity and Safety Pharmacology Studies of Indole Alkaloids Extract from Leaves of Alstonia scholaris (L.) R. Br. |
Yun-Li Zhao1,3, Min Su2, Jian-Hua Shang2,3, Xia Wang2, Guang-Lei Bao2, Jia Ma2, Qing-Di Sun4, Fang Yuan2, Jing-Kun Wang2, Xiao-Dong Luo1,3 |
1 State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming 650201, People's Republic of China; 2 Yunnan Institute of Medical Material, Kunming 650111, People's Republic of China; 3 Key Laboratory of Medicinal Chemistry for Natural Resource, Ministry of Education and Yunnan Province, School of Chemical Science and Technology, Yunnan University, Kunming 650091, People's Republic of China; 4 Jiangsu Nhwa Pharmaceutical Co., Ltd, Xuzhou 221009, People's Republic of China |
|
|
Abstract Indole alkaloids extract (IAAS) was prepared from leaves of Alstonia scholaris (L.) R. Br., an evergreen tropical plant widely distributed throughout the world. This plant has been used historically by the Dai ethnic people of China to treat respiratory diseases. This study evaluated the genotoxicity and safety pharmacology of IAAS to support clinical use. The bacterial reverse mutation (Ames) test, in vitro mammalian chromosomal aberration test, and in vivo mammalian erythrocyte micronucleus (MN) test were performed to evaluate genotoxicity. Mice were administered IAAS (240, 480, or 960 mg/kg bw) once orally to observe adverse central nervous system effects. Furthermore, beagle dogs were administered IAAS (10, 30, 60 mg/kg bw) once via the duodenum to evaluate its effects on the cardiovascular and respiratory systems. IAAS with or without S9-induced metabolic activation showed no genotoxicity in the Ames test up to 500 μg/plate, in the mammalian chromosomal aberration test up to 710 μg/mL, or in the MN test up to 800 mg/kg bw. No abnormal neurobehavioral effects were observed in mice following treatment with up to 960 mg/kg bw of IAAS. Moreover, blood pressure, heart rate, electrocardiogram parameters, and depth and rate of breathing in anesthetized beagle dogs did not differ among the IAAS doses or from the vehicle group. These data indicated that IAAS did not induce mutagenicity, clastogenicity, or genotoxicity, and no pharmaco-toxicological effects were observed in the respiratory, cardiovascular, or central nervous systems. Our results increased understanding of safety considerations associated with IAAS, and may indicate that IAAS is a possible drug candidate.
|
Keywords
Alstonia scholaris
Indole alkaloids extract
Genotoxicity
Safety pharmacology
Mice
Dogs
|
Fund:The authors are grateful to Yunnan Major Science and Technology Project (2019ZF003, 2019FY003004),the National Key Research and Development Program of China (2017YFC1704007), and the general program of applied basic research of Yunnan province (2019FB116) for partial financial support. |
Corresponding Authors:
Xiao-Dong Luo, Jing-Kun Wang
E-mail: xdluo@mail.kib.ac.cn;wjkyimm@163.com
|
Issue Date: 02 June 2020
|
|
|
1. P.T. Li, A.J.M. Leeuwenberg, D.J. Middleton, Ann. Mo. Bot. Garden 16, 154 (1995) 2. W.H. Zhang, Y. Liu, X.Q. Wang, P. Fang, H.Y. Song, J. Wang, T.J. Shan, Chin. J. Trop. Agric. 37, 104-112 (2017) 3. M.P. Singh, H. Panda, Medicinal Herbs with Their Formulations (Daya, New Delhi, 2005) 4. J. Cummings, Tech. Eng. 28, 33-33 (2014) 5. S. Vedavathy, A. Sudhakar, V. Mrdula, Anc. Sci. Life 16, 307-331 (1997) 6. H. Sharma, A. Kumar, J. Med. Plants Res. 5, 1107-1112 (2011) 7. S. Sen, R. Chakraborty, B. De, N. Devanna, J. For. Res. 22, 417-426 (2011) 8. Editorial Board of Chinese Flora, Chinese Academy of Sciences, Flora of China, vol. 63 (Scientific Press, Beijing, 1977), p. 90 9. M.K. Jaipuriar, Herbs of Tribal Land Jharkhand (Scientific Publishers, Jodhpur, 2007), pp. 24-25 10. B. Saikia, Indian J. Tradit. Knowl. 5, 529-530 (2006) 11. M. Ayyanar, S. Ignacimuthu, J. Ethnopharmacol. 102, 246-255 (2005) 12. Compiling Group of Yunnan Traditional Chinese Medicine. Yunnan People's Press, Kunming (1977) 13. X.H. Cai, J.H. Shang, T. Feng, X.D. Luo, Z. Nat. 65, 1164-1168 (2010) 14. Y.Y. Chen, J. Yang, X.W. Yang, A. Khan, L. Liu, B. Wang, Y.L. Zhao, Y.P. Liu, Z.T. Ding, X.D. Luo, Tetrahedron Lett. 57, 1754-1757 (2016) 15. X.W. Yang, C.W. Song, Y. Zhang, A. Khan, L.P. Jiang, Y.B. Chen, Y.P. Liu, X.D. Luo, Tetrahedron Lett. 56, 6715-6718 (2015) 16. X.W. Yang, X.J. Qin, Y.L. Zhao, P.K. Lunga, X.N. Li, S.Z. Jiang, G.G. Cheng, Y.P. Liu, X.D. Luo, Tetrahedron Lett. 55, 4593-4596 (2014) 17. X.W. Yang, X.D. Luo, P.K. Lunga, Y.L. Zhao, X.J. Qin, Y.Y. Chen, L. Liu, X.N. Li, Y.P. Liu, Tetrahedron 71, 3694-3698 (2015) 18. X.J. Qin, Y.L. Zhao, P.K. Lunga, X.W. Yang, C.W. Song, G.G. Cheng, L. Liu, Y.Y. Chen, Y.P. Liu, X.D. Luo, Tetrahedron 71, 4372-4378 (2015) 19. T. Feng, X.H. Cai, P.J. Zhao, Z.Z. Du, W.Q. Li, X.D. Luo, Planta Med. 75, 1537-1541 (2009) 20. X.W. Yang, C.P. Yang, L.P. Jiang, X.J. Qin, Y.P. Liu, Q.S. Shen, Y.B. Chen, X.D. Luo, Org. Lett. 16, 5808-5811 (2014) 21. Z.Q. Pan, X.J. Qin, Y.P. Liu, T. Wu, X.D. Luo, C.F. Xia, Org. Lett. 18, 654-657 (2016) 22. X.H. Cai, Z.Z. Du, X.D. Luo, Org. Lett. 9, 1817-1820 (2007) 23. X.H. Cai, Q.G. Tan, Y.P. Liu, T. Feng, Z.Z. Du, W.Q. Li, X.D. Luo, Org. Lett. 10, 577-580 (2008) 24. X.J. Qin, Y.L. Zhao, C.W. Song, B. Wang, Y.Y. Chen, L. Liu, Q. Li, D. Li, Y.P. Liu, X.D. Luo, Nat. Prod. Bioprospect. 5, 185-193 (2015) 25. Z.Y. Zhang, X.D. Luo, S. Li, J. Med. Plants Res. 8, 301-306 (2014) 26. H. Zhou, H.P. He, X.D. Luo, Y.H. Wang, X.W. Yang, Y.T. Di, X.J. Hao, Helv. Chim. Acta. 88, 2508-2512 (2005) 27. T. Feng, X.H. Cai, Z.Z. Du, X.D. Luo, Helv. Chim. Acta. 91, 2247-2251 (2008) 28. L. Liu, Y.Y. Chen, X.J. Qin, B. Wang, Q. Jin, Y.P. Liu, X.D. Luo, Fitoterapia 105, 160-164 (2015) 29. Y. Xu, T. Feng, X.H. Cai, X.D. Luo, Chin. J. Nat. Med. 7, 21-23 (2009) 30. G.S. Du, X.H. Cai, J.H. Shang, X.D. Luo, Chin. J. Nat. Med. 5, 259-262 (2007) 31. X.H. Cai, Y.P. Liu, T. Feng, X.D. Luo, Chin. J. Nat. Med. 6, 20-22 (2008) 32. G.S. Du, J.H. Shang, X.H. Cai, X.D. Luo, Acta Bot. Yunnanica. 29, 366-365 (2007) 33. J.H. Shang, X.H. Cai, T. Feng, Y.L. Zhao, J.K. Wang, L.Y. Zhang, M. Yan, X.D. Luo, J. Ethnopharmacol. 129, 174-181 (2010) 34. J.H. Shang, X.H. Cai, Y.L. Zhao, T. Feng, X.D. Luo, J. Ethnopharmacol. 129, 293-298 (2010) 35. Y.L. Zhao, J.H. Shang, S.B. Pu, H.S. Wang, B. Wang, L. Liu, Y.P. Liu, S.H. Mei, X.D. Luo, J. Ethnopharmacol. 178, 258-265 (2016) 36. Y.L. Zhao, J. Cao, J.H. Shang, Y.P. Liu, A. Khan, H.S. Wang, Y. Qian, L. Liu, M. Ye, X.D. Luo, Phytomedicine 27, 63-72 (2017) 37. Y.L. Zhao, Z.F. Yang, J.H. Shang, W.Y. Huang, B. Wang, X. Wei, A. Khan, Z.W. Yuan, Y.P. Liu, Y.F. Wang, X.H. Wang, X.D. Luo, J. Ethnopharmacol. 218, 69-75 (2018) 38. Y.Y. Hou, X.L. Cao, L.Y. Dong, L.Q. Wang, B.F. Cheng, Q. Shi, X.D. Luo, G. Bai, J. Chromatogr. A. 1227, 203-209 (2012) 39. Y.Y. Hou, X.L. Cao, L.Q. Wang, B.F. Cheng, L.Y. Dong, X.D. Luo, G. Bai, W.Y. Gao, J. Chromatogr. B. 908, 98-104 (2012) 40. J. Cao, H.M. Shen, Q. Wang, Y. Qian, H.C. Guo, K. Li, X. Qiao, D.A. Guo, X.D. Luo, M. Ye, J. Chromatogr. B 1026, 43-55 (2015) 41. M.S. Baliga, G.C. Jagetia, J.N. Ulloor, M.P. Baliga, P. Venkatesh, R. Reddy, K.V. Rao, B.S. Baliga, S. Devi, S.K. Raju, V. Veeresh, T.K. Reddy, K.L. Bairy, Toxicol. Lett. 151, 317-326 (2004) 42. G.C. Jagetia, M.S. Baliga, Birth Defects Res. B 68, 472-478 (2003) 43. CFDA, Good Laboratory Practice Regulations (CFDA Administration, Beijing, 2003), pp. 1-23 44. M.J. Runcie, L.G. Ulman, E.K. Potter, Regul. Pept. 60, 193-200 (1995) 45. S.M. Galloway, Environ. Mol. Mutagen. 312, 241-261 (1994) 46. K.Y. Shin, B.Y. Won, H.J. Ha, Y.S. Yun, H.G. Lee, Regul. Toxicol. Pharmacol. 71, 365-370 (2017) 47. J.S. Choi, E.J. Cheon, T.U. Kim, W.S. Moon, J.W. Kim, M.R. Kim, Biol. Pharm. Bull. 37, 1963-1970 (2014) 48. B.N. Ames, J. McCann, E. Yamasaki, Mutat. Res. 31, 347-364 (1975) 49. T. Matsushima, M. Hayashi, A. Matsuoka, M. Ishidate, K.F. Miura, H. Shimizu, Y. Suzuki, K. Morimoto, H. Ogura, K. Mure, Mutagenesis 14, 569-580 (1999) 50. H. Koyama, I. Yatabe, T. Ono, Exp. Cell Res. 62, 455-463 (1970) 51. J. Ashby, Mutat. Res. 156, 239-243 (1985) 52. S. Suárez, R.A. Sueiro, M. Araujo, F. Pardo, A. Alvarez, Mutat. Res. 626, 162-170 (2007) 53. M. Fenech, Mutat. Res. 455, 81-95 (2000) 54. ICH, S7A Safety Pharmacology Studies for Human Pharmaceuticals (2013) 55. R. Li, M.-J. Zi, Z.-P. Gou, Y.-L. Zhao, W.-T. Zhang, L. Fang, W.-Y. Cao, Y.-P. Zhao, Q.-N. Li, Y. Zhao, S.-G. Wang, H.-Y. Gao, M.-Y. Sun, X.-D. Luo, Z.-L. Xiong, R. Gao, Phytomedicine 61, 152828 (2019) 56. CFDA, Guideline for the testing of genotoxicity of drugs, Vol.[ZH] GPT2-1 (2007) 57. OECD, Guideline for Testing of Chemicals No. 471:Bacterial reverse mutation test (1997) 58. OECD, Guideline for the Testing of Chemicals No. 471:Bacterial Reverse Mutation Test (1997) 59. OECD, Guideline for Testing of Chemicals No. 473:In vitro mammalian chromosomal aberration test (2016) 60. D. Brusick, Genetic Toxicology, vol. 14 (Raven Press, New York, 1989) 61. OECD, Guideline for Testing of Chemicals No. 474:mammalian erythrocyte micronucleus test (2016) 62. Y.L. Zhao, M. Su, J.H. Shang, X. Wang, G.S.S. Njateng, G.L. Bao, J. Ma, Q.D. Sun, F. Yuan, J.K. Wang, X.D. Luo, Nat. Prod. Bioprospect. (2020). https://doi.org/10.1007/s13659-020-00237-1 63. CFDA, Guideline for the testing of safety pharmacology studies of drugs. In 2007; Vol.[Z] GPT1-1 64. ICH, S7A:Safety Pharmacology Studies for Human Pharmaceuticals (2001) |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|